Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Royalty Pharma's Enterprise Value is MXN608,043 Mil.
Royalty Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN30,846 Mil. Therefore, Royalty Pharma's EV-to-EBIT ratio for today is 19.71.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Royalty Pharma's Enterprise Value is MXN608,043 Mil.
Royalty Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN30,938 Mil. Therefore, Royalty Pharma's EV-to-EBITDA ratio for today is 19.65.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Royalty Pharma's Enterprise Value is MXN608,043 Mil.
Royalty Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN44,643 Mil. Therefore, Royalty Pharma's EV-to-Revenue ratio for today is 13.62.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Royalty Pharma's Enterprise Value is MXN608,043 Mil.
Royalty Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN47,587 Mil. Therefore, Royalty Pharma's EV-to-FCF ratio for today is 12.78.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Royalty Pharma (MEX:RPRXN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Royalty Pharma's current Enterprise Value is MXN608,043 Mil.
Royalty Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN30,846 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Royalty Pharma's current Enterprise Value is MXN608,043 Mil.
Royalty Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN30,938 Mil.
Royalty Pharma's current Enterprise Value is MXN608,043 Mil.
Royalty Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN44,643 Mil.
Royalty Pharma's current Enterprise Value is MXN608,043 Mil.
Royalty Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN47,587 Mil.
Royalty Pharma's current Enterprise Value is MXN608,043 Mil.
Royalty Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN47,587 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma Enterprise Value Related Terms
Royalty Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RPRXN vs BNTX, INSM, ROIV: Enterprise Value Comparison
For the Biotechnology subindustry, Royalty Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Royalty Pharma's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN608,043 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Enterprise Value of MXN608,043 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Enterprise Value too high?
Royalty Pharma's current Enterprise Value is MXN608,043 Mil. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Enterprise Value compare to BNTX and INSM?
Royalty Pharma's Enterprise Value of MXN608,043 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Enterprise Value is MXN608,043 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Enterprise Value of MXN608,043 Mil. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Enterprise Value is MXN608,043 Mil. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Enterprise Value is MXN608,043 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.
Key valuation signals for MEX:RPRXN:
Enterprise Value: MXN608,043 Mil
GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for MEX:RPRXN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RPRXN has been successfully added to your 
